Company (Symbol) | Offer Date |
Number Shares/Units (M)* |
Price Per Share/Unit ($) | Gross ($M)* |
Net ($M) |
Shares Out (M) | Post Offering Market Cap ($M)@ |
Lead UnderWriter** |
Other UnderWriters |
Albany Molecular Research Inc.1 (AMRI) |
2/3 |
2.82S |
20.00 |
$56.3 |
$52.9 | 12.8 | $256 | INGB | HQ |
AnorMED Inc.2 (TSE:AOM)*** | 2/25 |
5.2S |
$4.04 |
$20.8 |
$19.8 | 20.5 |
$82.8 |
NB | |
Invitrogen Corp.3 (IVGN) |
2/26 |
3.0S |
$15.00 | $45.0 | $41.1 | 12.6 |
$189 |
DLJ | WDR, PJI |
MorphoSys AG2 (Neuer Mkt:MORG)*** |
3/9 |
1.03S | $27.25 |
$28 |
$26 | 3.6 | $98 | DBAG |
|
Immtech International (IIMMT) | 4/27 | 1.15S |
$10.00 |
$11.5 |
$9.2 |
5.15 |
$51.5 | WRI |
NCHK, CES |
VaxGen Inc. (VXGN) |
6/30 |
3.56S |
$13.00 | $46.3 |
$42.1 | 11.3 | $146.4 |
PS |
PZC |
Genentech Inc. (NYSE:DNA) |
7/20 | 22S |
$97.00 |
$2,134 | # |
129.3 |
$12,542 | JPM |
GS, ML, WDR, |
BioMarin Pharmaceutical (BMRN) | 7/22 |
4.5S | $13.00 |
$58.5 |
$54.4 | 34.1 |
$443 | USBPJ |
VS, SSL, LSC |
Biopure Corp. |
7/30 | 3.5S |
$12.00 |
$42.0 |
$37.9 | 22.1 |
$265 |
JPM |
AHH, RWB |
January - July 1999 IPO TOTAL: $2,442.4 | |||||||||
NOTES: | |||||||||
* Number of shares (or units) sold in the offering includes those sold to satisfy overallotment options, in full or in part, when disclosed. Likewise, gross proceeds include revenues for the sale of shares (or units) to satisfy overallotment options, in full or in part, where applicable. | |||||||||
** See Underwriters' Key on Page 6 | |||||||||
***Converted to U.S. dollars based on exchange rate at the time of the offering. | |||||||||
@ Market capitalization calculated is based on offering price. | |||||||||
LSE = London Stock Exchange; ND = Not disclosed, reported and/or available | |||||||||
1 Albany Molecular Research Inc. had originally filed a prospectus for an initial public offering (IPO) of 2.2M shares priced between $15 and $17 each on 7/9/98. The company postponed the offering in early September due to market conditions, but reactivated it in January 1999, offering the same number of shares at a higher price range. However, it ended up selling 0.3M more shares than planned at $1.00 above the high end of the offering range. | |||||||||
2 AnorMED Inc.'s IPO occurred in Canada; MorphoSys' was in Germany. | |||||||||
3 On 1/28/99, Invitrogen Corp. raised the number of shares to be offered in its IPO to 3.5M from 3M. The company sold 3M shares, while existing stockholders sold 0.5M. | |||||||||
# Roche Holdings Inc., Genentech's major stockholder, offered all the shares of common stock in this transaction and | |||||||||
received the proceeds of the offering. | |||||||||
To read more on related topics, click on one of the words below.